ARTICLE | Company News
Elan, RxKinetix deal
June 9, 2003 7:00 AM UTC
The companies ended their deal to identify and develop compound formulations to treat oral mucositis and other oral cavity diseases. As ended, RxKinetix acquired exclusive rights to the JV's RK-0202 o...